Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BK virus-specific cytotoxic T lymphocytes (CHOP)
- Development stage
- Unknown
- Lead developer
- Children's Hospital of Philadelphia
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
BK virus-specific cytotoxic T lymphocytes (CTLs) are an adoptive cellular immunotherapy developed by the Children's Hospital of Philadelphia (CHOP) for treating BK polyomavirus (BKV) infections in immunocompromised patients, such as those undergoing hematopoietic stem cell or renal transplantation. The therapy consists of T cells manufactured to specifically target BKV antigens, including the VP1 capsid protein and the large T antigen. These cells are typically produced using the Miltenyi CliniMACS Prodigy system with gamma-capture technology, allowing for the selection of virus-reactive T cells from HLA-matched donors. By replenishing the patient's immune system with virus-specific effectors, the treatment aims to control viral replication and resolve clinical complications like hemorrhagic cystitis and BKV-associated nephropathy.
- Other names
- BK-virus specific CTLsBK-CTLsBK virus-specific T cells
02
Targets
BK polyomavirus large T antigen-derived peptide–HLA complexBK virus VP1 capsid protein-derived peptide presented by MHC class I
Beyond the preview
Go deeper on BK virus-specific cytotoxic T lymphocytes (CHOP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BK virus-specific cytotoxic T lymphocytes (CHOP).